Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer

BACKGROUND: This study was designed to evaluate toxicity and preliminary efficacy of 2 cycles of concomitant standard dose/schedule of (153)Sm-lexidronam plus Q 3 weeks schedule escalating doses of docetaxel in metastatic castration-resistant prostate cancer (mCRPC). METHODS: mCRPC patients with pro...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lin, Jianqing, Sinibaldi, Victoria J., Carducci, Michael A., Denmeade, Samuel, Song, Danny, DeWeese, Theodore, Eisenberger, Mario A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3483074/
https://ncbi.nlm.nih.gov/pubmed/19962920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2009.10.003
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller